Elevated Triglyceride Level Is Independently Associated with Increased All-Cause Mortality in Patients with Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry

Circulation: Cardiovascular Quality and Outcomes

Volumn 9, Issue 2, 2016, Pages 100-108

  Klempfner, Robert ^a   Erez, Aharon ^a   Sagit, Ben Zekry ^a,b   Goldenberg, Ilan ^a,b,c   Fisman, Enrique ^a,b   Kopel, Eran ^d   Shlomo, Nir ^a   Israel, Ariel ^a,b   Tenenbaum, Alexander ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d MINISTRY OF HEALTH   (Israel)

Author keywords

cholesterol HDL; coronary disease; hypertriglyceridemia; mortality; triglycerides

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; BEZAFIBRATE; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIAC PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REGISTER; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; UPREGULATION;

AGED; BEZAFIBRATE; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UP-REGULATION;

EID: 84962549699     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.115.002104     Document Type: Article

References (45)

1. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011 123 2292 2333. doi: 10.1161/CIR.0b013e3182160726.
2. Nordestgaard BG, Varbo A., Triglycerides and cardiovascular disease. Lancet 2014 384 626 635. doi: 10.1016/S0140-6736(14)61177-6.
3. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR Jr, O'Grady HK, Davis CE., Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993 328 1220 1225. doi: 10.1056/NEJM199304293281702.
4. Laakso M, Lehto S, Penttilä I, Pyörälä K., Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993 88 4 pt 1 1421 1430
5. West KM, Ahuja MM, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, Grab B, Grabauskas V, Jarrett RJ, Kosaka K., The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 1983 6 361 369
6. Fontbonne A, Eschwège E, Cambien F, Richard JL, Ducimetière P, Thibult N, Warnet JM, Claude JR, Rosselin GE., Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989 32 300 304
7. Bass KM, Newschaffer CJ, Klag MJ, Bush TL., Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993 153 2209 2216
8. Austin MA, McKnight B, Edwards KL, Bradley CM, McNeely MJ, Psaty BM, Brunzell JD, Motulsky AG., Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000 101 2777 2782
9. He Y, Lam TH, Li LS, Li LS, He SF, Liang BQ., Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China. Ann Epidemiol 2004 14 1 7
10. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A., Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007 298 299 308. doi: 10.1001/jama.298.3.299.
11. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM., Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007 298 309 316. doi: 10.1001/jama.298.3.309.
12. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J, Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009 302 1993 2000. doi: 10.1001/jama.2009.1619.
13. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ., Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care 2005 28 2508 2513
14. Kasai T, Miyauchi K, Kurata T, Ohta H, Okazaki S, Miyazaki T, Kajimoto K, Kubota N, Daida H., Prognostic value of the metabolic syndrome for long-term outcomes in patients undergoing percutaneous coronary intervention. Circ J 2006 70 1531 1537
15. Anderson JL, Horne BD, Jones HU, Reyna SP, Carlquist JF, Bair TL, Pearson RR, Lappé DL, Muhlestein JB, Intermountain Heart Collaborative (IHC) Study Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease? Cardiology 2004 101 185 193. doi: 10.1159/000076695.
16. Goldbourt U, Brunner D, Behar S, Reicher-Reiss H., Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J 1998 19 suppl H H42 H47
17. Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Circulation 1992 86 839 848
18. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Weisbort J, Mandelzweig L., Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993 71 909 915
19. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U., Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol 1996 16 351 356
20. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002 106 3143 3421
21. Therneau TM, Crowson CS, Atkinson EJ., Adjusted Survival Curves. 2015. https://cran.r-project.org/web/packages/survival/vignettes/adjcurve.pdf. Accessed October 31, 2015
22. Cheng YT, Liu TJ, Lai HC, Lee WL, Ho HY, Su CS, Liu CN, Wang KY., Lower serum triglyceride level is a risk factor for in-hospital and late major adverse events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention-a cohort study. BMC Cardiovasc Disord 2014 14 143. doi: 10.1186/1471-2261-14-143.
23. Sprecher DL, Pearce GL, Cosgrove DM, Lytle BW, Loop FD, Pashkow FJ., Relation of serum triglyceride levels to survival after coronary artery bypass grafting. Am J Cardiol 2000 86 285 288
24. Yun KH, Shin IS, Rhee SJ, Lee EM, Yoo NJ, Kim NH, Oh SK, Jeong JW., Clinical significance of on-treatment triglyceride level in patients treated by percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Korean J Intern Med 2009 24 330 336. doi: 10.3904/kjim.2009.24.4.330.
25. Kasai T, Miyauchi K, Yanagisawa N, Kajimoto K, Kubota N, Ogita M, Tsuboi S, Amano A, Daida H., Mortality risk of triglyceride levels in patients with coronary artery disease. Heart 2013 99 22 29. doi: 10.1136/heartjnl-2012-302689.
26. Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, Goldbourt U., Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 1999 100 475 482
27. Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkand BM, Schonfeld G, Jacobs D, Frantz ID Jr., Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study. Circulation 1980 61 302 315
28. Almeda-Valdes P, Cuevas-Ramos D, Mehta R, Muñoz-Hernandez L, Cruz-Bautista I, Perez-Mendez O, Tusie-Luna MT, Gomez-Perez FJ, Pajukanta P, Matikainen N, Taskinen MR, Aguilar-Salinas CA., Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia. BMC Endocr Disord 2014 14 90. doi: 10.1186/1472-6823-14-90.
29. Bjornstad P, Maahs DM, Wadwa RP, Pyle L, Rewers M, Eckel RH, Snell-Bergeon JK., Plasma triglycerides predict incident albuminuria and progression of coronary artery calcification in adults with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes Study. J Clin Lipidol 2014 8 576 583. doi: 10.1016/j.jacl.2014.08.008.
30. Triglyceride Coronary Disease Genetics C, Emerging Risk Factors C Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J., Triglyceride Coronary Disease Genetics C, Emerging Risk Factors C Triglyceride-mediated pathways and coronary disease: Collaborative analysis of 101 studies. Lancet 2010 375 1634 1639
31. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V., Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007 115 450 458. doi: 10.1161/CIRCULATIONAHA.106.637793.
32. Miselli MA, Nora ED, Passaro A, Tomasi F, Zuliani G., Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study. Cardiovasc Diabetol 2014 13 135. doi: 10.1186/s12933-014-0135-6.
33. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S., Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012 380 572 580. doi: 10.1016/S0140-6736(12)60312-2.
34. Tenenbaum A, Klempfner R, Fisman EZ., Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol 2014 13 159. doi: 10.1186/s12933-014-0159-y.
35. Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A., Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013 34 1826 1833. doi: 10.1093/eurheartj/ehs431.
36. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR., A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008 322 1702 1705. doi: 10.1126/science.1161524.
37. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A., Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014 371 32 41. doi: 10.1056/NEJMoa1308027.
38. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, Lu Y, Tang ZZ, Zhang H, Hindy G, Masca N, Stirrups K, Kanoni S, Do R, Jun G, Hu Y, Kang HM, Xue C, Goel A, Farrall M, Duga S, Merlini PA, Asselta R, Girelli D, Olivieri O, Martinelli N, Yin W, Reilly D, Speliotes E, Fox CS, Hveem K, Holmen OL, Nikpay M, Farlow DN, Assimes TL, Franceschini N, Robinson J, North KE, Martin LW, DePristo M, Gupta N, Escher SA, Jansson JH, Van Zuydam N, Palmer CN, Wareham N, Koch W, Meitinger T, Peters A, Lieb W, Erbel R, Konig IR, Kruppa J, Degenhardt F, Gottesman O, Bottinger EP, O'Donnell CJ, Psaty BM, Ballantyne CM, Abecasis G, Ordovas JM, Melander O, Watkins H, Orho-Melander M, Ardissino D, Loos RJ, McPherson R, Willer CJ, Erdmann J, Hall AS, Samani NJ, Deloukas P, Schunkert H, Wilson JG, Kooperberg C, Rich SS, Tracy RP, Lin DY, Altshuler D, Gabriel S, Nickerson DA, Jarvik GP, Cupples LA, Reiner AP, Boerwinkle E, Kathiresan S., The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute Loss-of-function mutations in apoc3, triglycerides, and coronary disease. N Engl J Med 2014 371 22 31. doi: 10.1056/NEJMoa1307095.
39. The BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000 102 21 27
40. Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP, ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 362 1563 1574. doi: 10.1056/NEJMoa1001282.
41. Tenenbaum A, Fisman EZ., "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol 2010 9 24. doi: 10.1186/1475-2840-9-24.
42. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009 32 493 498. doi: 10.2337/dc08-1543.
43. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH., Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992 85 37 45
44. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB, VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001 285 1585 1591
45. Goldenberg I, Benderly M, Goldbourt U, BIP Study Group Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. J Am Coll Cardiol 2008 51 459 465. doi: 10.1016/j.jacc.2007.09.048.